22.37
Neurogene Inc Borsa (NGNE) Ultime notizie
What drives Neurogene Inc. stock priceAccelerated capital growth - Autocar Professional
Neurogene Inc. Stock Analysis and ForecastExplosive capital gains - PrintWeekIndia
Rett bet set includes Neurogene, Taysha gene therapies - BioWorld MedTech
Is Neurogene Inc. a good long term investmentHigh-yield portfolio picks - Autocar Professional
What analysts say about Neurogene Inc. stockFree Market Dynamics Reports - jammulinksnews.com
What makes Neurogene Inc. stock price move sharplyReal Time Stock Signal - Newser
how neurogene inc. stock performs during market volatilityDefensive Stock Picks with Upside - Newser
How Neurogene Inc. stock performs during market volatilityHigh Return Conservative Stocks - Newser
Why Neurogene Inc. stock attracts strong analyst attentionFree Investment Community - Newser
Neurogene announces inducement grants - Medical Buyer
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Neurogene jumps as FDA approves rare gene therapy trial design - TradingView
Stifel reiterates Buy rating on Neurogene stock, backs pivotal trial design - Investing.com
FDA approves Neurogene’s Rett syndrome gene therapy registrational trial design - Investing.com
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
Neurogene Inc.(NasdaqGM: NGNE) dropped from Russell 3000E Growth Index - MarketScreener
Craig-Hallum bullish on Neurogene, initiates with a Buy - Yahoo Finance
Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at Craig Hallum - Defense World
Neurogene (NGNE) Receives New Buy Rating from Craig-Hallum | NGN - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for - GuruFocus
Neurogene (NGNE) Receives Positive Coverage with a $50 Price Tar - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for Rett Syndrome | NGNE Stock News - GuruFocus
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Investing.com Nigeria
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):